��躰�肽𨯙嚙踝蕭�椬��㮖����𠺪蕭��辷蕭
��躰�頣蕭皛抵�䈑蕭嚙踝蕭膌见�躰�肽𨯙
��躰�肽𨯙嚙踝蕭颲瑁𨯙�𢥫嚙質�嚙踢�𧶏蕭薳��𨯙
��躰釭嚙賢��𨯙嚙賡ㄤ��躰釭嚙賭�對蕭嚙�
��躰釭嚙賢��𨯙嚙踝蕭蒺矋蕭嚙賣���辷蕭
��躰�頣蕭嚙質𨯙��鞱�矋蕭��躰�肽𨯙嚙踢岡芾働嚙�
��躰�頣蕭皛抵�䈑蕭嚙踝蕭嚙賢�磰𨯙嚙踢﹜���躰�肽𨯙��躰�肽𨯙
嚙賭麩��躰�肽𨯙嚙賭�𡑒𨯙��躰�肽𨯙��躰�肽𨯙
��躰腺鈭�䁥滩𨯙嚙賡�嚙踝蕭��躰�頣蕭�迚�𨯙
��躰�肽𨯙嚙踝蕭嚙踢�佅嚙賢�躰�肽𨯙嚙踝蕭�迚�𨯙
��躰�肽𨯙嚙賜�嚙踝蕭臐�鳴蕭�莎蕭撠𩤃蕭臐�航𨯙��躰郭嚙踢岸��𨯙��辷蕭
��躰�肽𨯙��躰�肽𨯙嚙賡做嚙踢╱ｇ蕭暻芸�躰腺�𧊋臐�航𨯙��躰�肽𨯙
嚙踝蕭��嚙質�磰𨯙��躰�肽𨯙嚙賢䐓��躰釭臐�嚙踝蕭嚙踝蕭��辷蕭
��躰釭嚙賢��𨯙嚙踢�鍦�躰�栶�笔�辷蕭
��躰都嚙賢�躰腺嚙賬���躰腺嚙賢��
��躰酗��𥕦�躰郭��嚙賢��𨯙��鮋ㄙ
��躰都嚙賢�躰腺嚙賬���躰�肽𨯙��躰�肽𨯙��辷蕭
��躰都嚙賢�躰腺嚙賬�嚙踝蕭嚙質𨯙��躰�肽𨯙
��躰酗藆�坿���嚙質�𨅯�𡑒��𨯙��辷蕭
��躰酗��𨥈蕭嚙踢�航𨯙嚙踝蕭嚙踝蕭臐��𨯙
嚙踢坎萘���朞𨯙�坾蝞�嚙賢�躰�肽𨯙��辷蕭
��躰閉瘣賢�躰酗嚙踢�航𨯙�����𨯙��辷蕭
嚙踢△�嚙踝蕭嚙質𨯙嚙踝蕭璇寡𨯙��辷蕭
��躰�肽𨯙��躰腺銝滚��𨯙��躰�肽𨯙��躰�肽𨯙
��躰�肽𨯙��𥕦�页蕭���𧒆䕘蕭薴ㄟ��躰腺��舘�舘𨯙
��躰腺鈭�䁥滩𨯙嚙賡�嚙踢�𦴣��躰�肽𨯙��躰�肽𨯙
��躰閉�蕟��躰�肽𨯙��嚙踝蕭�𨯙��琜蕭藃�讛𨯙��辷蕭
嚙踝蕭薳閦�𥕦�𩤃蕭嚙質𨯙��躰�肽𨯙��躰�肽𨯙
嚙踝蕭薳閦�𥕦�𩤃蕭嚙質𨯙��躰部薴钟��辷蕭
��躰腺嚙賣�坿𨯙��嚙賣Ⅰ�𨯙��躰�肽𨯙��辷蕭
��躰腺嚙賣�坿𨯙��嚙賜�橘蕭嚙質�芷礆嚙�
嚙踝蕭臐号艟洽嚙踝蕭��磰𨯙��躰�肽𨯙��辷蕭
��躰�肽𨯙嚙賢𠘕嚙賢𠹭��㚁蕭銧游�辷蕭
��躰�肽𨯙��𥟇䠋�𨯙��躰�肽𨯙��𥪮�航𨯙
嚙踝蕭�緾嚙賢�躰郭嚙賭�𡑒𨯙嚙踝蕭嚙�
��躰�肽𨯙嚙踢╱Ｚ躀臐��𨯙��躰�肽𨯙��辷蕭
嚙踝蕭艟妟��𥕦�躰郭嚙賭�𤏸𨯙��躰�肽𨯙��辷蕭
嚙踝蕭嚙質𨯙�𩸭嚙踢﹛痹蕭�𩣪嚙賣䠋�𨯙嚙踝蕭嚙踝蕭�佞𧒆��辷蕭
嚙踝蕭嚙質𨯙�𩸭嚙踢﹛痹蕭�𩣪嚙賣䠋�𨯙嚙踝蕭擗�𠯫�𧒆��辷蕭
嚙踝蕭嚙質𨯙�𩸭嚙踢﹛痹蕭�𩣪嚙賣䠋�𨯙嚙踝蕭憍辷蕭�莎蕭嚙質鷄嚙踝蕭
��躰�肽𨯙��𥕦��𨯙嚙賜�皜脩腦嚙踢𧒆��辷蕭
��躰�肽𨯙��𥕦��𨯙嚙賜�皜賂蕭�樹𧒆��辷蕭
嚙踝蕭艟妟��𥕦�躰釭�𡁜�躰腺嚙踝蕭藂��𨯙��躰釭蝮�蕭�𧒆��辷蕭
嚙踝蕭艟妟��𥕦�躰釭�𡁜�躰腺嚙踝蕭藂��𨯙��躰郭嚙賜�樹𧒆��辷蕭
��躰腺�亙�滩𨯙��躰�頣蕭��𡏭𨯙��躰�肽𨯙�����痹蕭嚙�
��躰�肽𨯙嚙踢𧒆䕘蕭嚙踢孜讛𨯙��躰�肽𨯙��辷蕭
嚙踝蕭���蕭�䁥滩𨯙��琜蕭�迚�𨯙��辷蕭
��躰�肽𨯙��躰郭�𨺗��躰�肽𨯙
��躰�肽𨯙��躰�肽𨯙嚙踝蕭隤抵���嚙賬答�𨯙��躰�肽𨯙
尚立(3360)
月營收
季盈餘
2025/02/01
14.35元 (尚立股價)
2025/02/01
52.46% (年增率)
420百萬元 (營收)
尚立(3360) 年度營收走勢圖
12
871百萬/月 (110年)
874百萬/月 (111年)
402百萬/月 (112年)
490百萬/月 (113年)
N/A百萬/月 (114年)
尚立(3360)月營收明細
單位：仟元
年/月
營收
月增率
去年同期
年增率
累計營收
年增率
114/02
419,751
2.44%
275,322
52.46%
829,519
13.97%
114/01
409,768
-16.50%
452,534
-9.45%
409,768
-9.45%
113/12
490,755
-11.22%
402,815
21.83%
6,263,130
-13.91%
113/11
552,771
-19.32%
441,296
25.26%
5,772,375
-16.00%
113/10
685,167
9.74%
403,540
69.79%
5,219,604
-18.83%
113/09
624,356
-0.16%
388,947
60.52%
4,534,437
-24.77%
113/08
625,343
27.22%
355,570
75.87%
3,910,081
-30.65%
113/07
491,549
-3.97%
387,770
26.76%
3,284,738
-37.82%
113/06
511,896
-11.34%
745,126
-31.30%
2,793,189
-42.94%
113/05
577,361
-2.38%
949,363
-39.18%
2,281,293
-45.03%
113/04
591,460
53.78%
951,042
-37.81%
1,703,932
-46.76%
113/03
384,616
39.70%
921,437
-58.26%
1,112,472
-50.54%
113/02
275,322
-39.16%
642,369
-57.14%
727,856
-45.19%
113/01
452,534
12.34%
685,501
-33.98%
452,534
-33.98%
112/12
402,815
-8.72%
874,125
-53.92%
7,274,776
-27.98%
112/11
441,296
9.36%
701,274
-37.07%
6,871,961
-25.52%
112/10
403,540
3.75%
711,437
-43.28%
6,430,665
-24.57%
112/09
388,947
9.39%
981,991
-60.39%
6,027,125
-22.87%
112/08
355,570
-8.30%
1,005,064
-64.62%
5,638,178
-17.48%
112/07
387,770
-47.96%
677,652
-42.78%
5,282,608
-9.35%
112/06
745,126
-21.51%
505,384
47.44%
4,894,838
-4.95%
112/05
949,363
-0.18%
646,691
46.80%
4,149,712
-10.65%
112/04
951,042
3.21%
815,170
16.67%
3,200,349
-19.94%
112/03
921,437
43.44%
1,166,469
-21.01%
2,249,307
-29.32%
112/02
642,369
-6.29%
967,327
-33.59%
1,327,870
-34.13%
112/01
685,501
-21.58%
1,048,544
-34.62%
685,501
-34.62%
111/12
874,125
24.65%
871,548
0.30%
10,101,128
7.58%
111/11
701,274
-1.43%
785,135
-10.68%
9,227,003
8.33%
111/10
711,437
-27.55%
749,653
-5.10%
8,525,729
10.26%
111/09
981,991
-2.30%
656,602
49.56%
7,814,292
11.91%
111/08
1,005,064
48.32%
718,674
39.85%
6,832,301
8.00%
111/07
677,652
34.09%
685,649
-1.17%
5,827,237
3.92%
111/06
505,384
-21.85%
563,427
-10.30%
5,149,585
4.63%
111/05
646,691
-20.67%
714,925
-9.54%
4,644,201
6.56%
111/04
815,170
-30.12%
909,418
-10.36%
3,997,510
9.72%
111/03
1,166,469
20.59%
699,757
66.70%
3,182,340
16.40%
111/02
967,327
-7.75%
997,925
-3.07%
2,015,871
-0.90%
111/01
1,048,544
20.31%
1,048,544
110/12
871,548
11.01%
9,389,024
110/11
785,135
4.73%
8,517,476
110/10
749,653
14.17%
7,732,341
110/09
656,602
-8.64%
6,982,688
110/08
718,674
4.82%
6,326,086
110/07
685,649
21.69%
5,607,412
110/06
563,427
-21.19%
4,921,763
110/05
714,925
-21.39%
4,358,336
110/04
909,418
29.96%
3,643,411
110/03
699,757
-29.88%
2,733,993
說明：自2013年起上市櫃公司因IFRSs會計準則規範，每月公告的營收必須是合併營收，不再公告非合併營收。2012年(含)前，合併營收是採自願公告。
